Pro Medicus Ltd (PME)

Currency in AUD
210.42
-1.71(-0.81%)
Closed·
PME is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
205.19211.73
52 wk Range
107.75336.00
Key Statistics
Bid/Ask
210.00 / 209.99
Prev. Close
210.42
Open
206
Day's Range
205.19-211.73
52 wk Range
107.75-336
Volume
202.41K
Average Volume (3m)
329.13K
1-Year Change
-33.1321%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PME Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
190.74
Downside
-9.35%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Pro Medicus Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

11 Buy
3 Hold
1 Sell
Ratings:
15 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 190.74
(-9.35% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Hold192.60-8.47%147.00DowngradeJul 08, 2026
CLSA
Buy250.00+18.81%170.00MaintainJul 07, 2026
Citi
Buy240.00+14.06%245.00MaintainJul 05, 2026
JPMorgan
Buy207.90-1.20%205.50MaintainMay 19, 2026
RBC Capital
Hold195.00-7.33%190.00MaintainMay 19, 2026

Pro Medicus Ltd Earnings Call Summary for H1/2026

  • Pro Medicus reported record H1 2026 performance with 28.4% revenue growth and ~30% increase in underlying EBIT, though stock fell 19.71% post-announcement.
  • Interim dividend increased by 28% to AUD 0.32 per share, fully franked, with cash and investments up 5.3%.
  • Company launched new cardiology suite, expanded AI capabilities, and is developing digital pathology products as part of its enterprise imaging strategy.
  • CEO Dr. Sam Hupert projects forward revenue to exceed AUD 1 billion over next five years, with expectations for stronger H2 FY2026 performance.
  • Management views AI integration as 'a plus rather than a threat,' focusing on both proprietary AI development and strategic third-party partnerships.
Last Updated: 2026/02/12, 03:42
Read Full Transcript

Earnings

Latest Release
Jun 03, 2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.24%
Dividend Yield
0.29%
Industry Median 1.37%
Annualised payout
0.62
Paid unevenly
5-Years Growth
+36.68%
Growth Streak

PME Income Statement

Compare PME to Peers and Sector

Metrics to compare
PME
Peers
Sector
Relationship
P/E Ratio
93.7x18.3x−0.4x
PEG Ratio
0.670.120.00
Price/Book
56.5x2.0x2.6x
Price / LTM Sales
91.4x1.6x3.0x
Upside (Analyst Target)
−4.3%29.4%51.9%
Fair Value Upside
Unlock15.3%9.4%Unlock

Pro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and communication system (PACS)/digital imaging software. It also provides Visage RIS, a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform for secure email and integration products. In addition, the company offers Visage Ease, a mobile application that provides users access to medical imaging results; and Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
14,45M13,83%3,07B
Other Institutional Investors
16,18M15,49%3,43B
Public Companies & Retail Investors
73,84M70,68%15,66B
Total
104,47M100,00%22,16B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
AustralianSuper5,01%5 237 4861 111 028
Australian Super Pty Ltd5,01%5 237 4861 111 028

FAQ

What Is the Pro Medicus Ltd (PME) Stock Price Today?

The Pro Medicus Ltd stock price today is 210,42 AUD.

What Stock Exchange Does Pro Medicus Ltd Trade On?

Pro Medicus Ltd is listed and trades on the Sydney Stock Exchange.

What Is the Stock Symbol for Pro Medicus Ltd?

The stock symbol for Pro Medicus Ltd is "PME."

Does Pro Medicus Ltd Pay Dividends? What’s The Current Dividend Yield?

The Pro Medicus Ltd dividend yield is 0.29%.

What Is the Pro Medicus Ltd Market Cap?

As of today, Pro Medicus Ltd market cap is 21,98B AUD.

What Is Pro Medicus Ltd's Earnings Per Share (TTM)?

The Pro Medicus Ltd EPS (TTM) is 2,24.

When Is the Next Pro Medicus Ltd Earnings Date?

Pro Medicus Ltd will release its next earnings report on Aug 19, 2026.

From a Technical Analysis Perspective, Is PME a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Pro Medicus Ltd Stock Split?

Pro Medicus Ltd has split 0 times.

How Many Employees Does Pro Medicus Ltd Have?

Pro Medicus Ltd has 132 employees.

What is the current trading status of Pro Medicus Ltd (PME)?

As of Jul 09, 2026, Pro Medicus Ltd (PME) is trading at a price of 210,42 AUD, with a previous close of 210,42 AUD. The stock has fluctuated within a day range of 205,19 AUD to 211,73 AUD, while its 52-week range spans from 107,75 AUD to 336,00 AUD.

What Is Pro Medicus Ltd (PME) Price Target According to Analysts?

The average 12-month price target for Pro Medicus Ltd is 190,74 AUD, with a high estimate of 250 AUD and a low estimate of 54 AUD. 11 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an -9,35% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.